BR112014016575A2 - método para o tratamento da doença de lyme - Google Patents

método para o tratamento da doença de lyme

Info

Publication number
BR112014016575A2
BR112014016575A2 BR112014016575A BR112014016575A BR112014016575A2 BR 112014016575 A2 BR112014016575 A2 BR 112014016575A2 BR 112014016575 A BR112014016575 A BR 112014016575A BR 112014016575 A BR112014016575 A BR 112014016575A BR 112014016575 A2 BR112014016575 A2 BR 112014016575A2
Authority
BR
Brazil
Prior art keywords
lyme disease
treating lyme
treating
cefovecin
animals
Prior art date
Application number
BR112014016575A
Other languages
English (en)
Other versions
BR112014016575A8 (pt
Inventor
L Haber Christopher
F M Meeus Patrick
Original Assignee
Zoetis Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zoetis Llc filed Critical Zoetis Llc
Publication of BR112014016575A2 publication Critical patent/BR112014016575A2/pt
Publication of BR112014016575A8 publication Critical patent/BR112014016575A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

resumo "método para o tratamento da doença de lyme" a presente invenção fornece um método para o tratamento de doença de lyme e/ou a infecção borrelia em animais que compreende a administração de uma quantidade terapeuticamente eficaz de cefovecina a um animal em necessidade da mesma.
BR112014016575A 2012-01-03 2012-12-20 método para o tratamento da doença de lyme BR112014016575A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261582742P 2012-01-03 2012-01-03
PCT/US2012/070753 WO2013103531A1 (en) 2012-01-03 2012-12-20 A method for treating lyme disease

Publications (2)

Publication Number Publication Date
BR112014016575A2 true BR112014016575A2 (pt) 2017-06-13
BR112014016575A8 BR112014016575A8 (pt) 2017-07-04

Family

ID=47459202

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014016575A BR112014016575A8 (pt) 2012-01-03 2012-12-20 método para o tratamento da doença de lyme

Country Status (10)

Country Link
US (1) US9265771B2 (pt)
EP (1) EP2800570A1 (pt)
JP (1) JP2013139443A (pt)
AR (1) AR093734A1 (pt)
AU (1) AU2012363652A1 (pt)
BR (1) BR112014016575A8 (pt)
CA (1) CA2860574C (pt)
MX (1) MX2014008194A (pt)
WO (1) WO2013103531A1 (pt)
ZA (1) ZA201405451B (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190008848A1 (en) * 2015-08-21 2019-01-10 The Johns Hopkins University Identification of additional anti-persister activity against borrelia burgdorferi from an fda drug library

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011142731A2 (en) 2010-05-14 2011-11-17 Mahmut Bilgic Formulations comprising a third generation cephalosporin and clavulanic acid

Also Published As

Publication number Publication date
MX2014008194A (es) 2015-03-19
BR112014016575A8 (pt) 2017-07-04
US20140343003A1 (en) 2014-11-20
CA2860574C (en) 2017-01-03
AU2012363652A1 (en) 2014-07-24
AR093734A1 (es) 2015-06-24
US9265771B2 (en) 2016-02-23
ZA201405451B (en) 2015-12-23
EP2800570A1 (en) 2014-11-12
WO2013103531A1 (en) 2013-07-11
JP2013139443A (ja) 2013-07-18
CA2860574A1 (en) 2013-07-11

Similar Documents

Publication Publication Date Title
BR112017003546A2 (pt) amidas heterocíclicas como inibidores de rip1 quinase como medicamentos
BR112015027282A2 (pt) fenfluramina para uso no tratamento de síndrome de dravet
CR20120638A (es) Métodos de terapia combinada para tratar enfermedades proliferativas
BR112015006623A2 (pt) laquinimod e pridopidina para o tratamento de doenças neurodegenerativas
BR112013010665A2 (pt) sistema para tratar uma condição médica em seres humanos ou animais, método de tratamento de uma condição médica em seres humanos ou animais com um ou mais agentes terapèuticos, dispositivo para tratar uma condição médica em seres humanos ou animais e dispositivo de cateter para administrar um líquido a um vaso sanguíneo
BR112014000671A2 (pt) métodos para determinar o teor de uma proteína de interesse neuronalmente derivada, para determinar a eficácia terapêutica de um agente terapêutico para tratar mal de alzheimer, e, para determinar o acoplamento ao alvo de um anticorpo terapêutico ligado em uma proteína de interesse neuronalmente derivada
RU2018145985A (ru) Антагонисты активина-actrii и их применение для лечения нарушений костной ткани и других нарушений
BR112013030894A2 (pt) moduladores do sistema imune
BR112014014783A2 (pt) moléculas de inibidor de jnk para tratamento de várias doenças
BR112014010803A2 (pt) método de tratamento
BR112015022465A2 (pt) método para tratamento não-tóxico para síndrome de abstinência de drogas
BR112013018919A2 (pt) composições de nanopartículas vazias e seu uso para tratamento de problemas dermatológicos
BRPI1009860A2 (pt) composto, uso do mesmo, composição farmacêutica e método para tratamento terapêutico ou prevenção de doenças em humanos ou animais
BR112013006673A2 (pt) produtos terapêuticos para câncer de mama
BR112015009503A2 (pt) dispostivo de tratamento extracorporal do sangue
BR112015007814A2 (pt) diagnóstico, prevenção e tratamento de doenças da articulação
BR112016027043A8 (pt) combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer
BR112014019399A2 (pt) métodos de tratamento da fibrose
BR112015005339A2 (pt) composições farmacêuticas tópicas ou cosméticas, método para tratar, prevenir ou melhorar uma condição ou transtorno que afeta a pele, membranas mucosas, cabelo, ou unhas de um animal, composição de auxílio sexual, método para tratar uma condição de transtorno de um animal causada por ou associada a inflamação, métodos para tratar uma articulação de um animal, métodos para melhorar o desempenho de uma articulação de um animal, composições elastoméricas gelatinosas, artigos molgados e artigos flexíveis
BR112017017599A2 (pt) métodos para modular respostas imunológicas e inflamatórias pela administração de uma biomassa algal
BR112013010136A2 (pt) vacina, composição terapêutica e métodos para o tratamento ou inibição de gliblastoma
BR112015008459A2 (pt) método veterinário de aliviar a aversão ao ruído
BR112018012765A2 (pt) composição, método para tratamento, prevenção e/ou melhora de uma afecção médica, e, dispositivo mecânico.
BR112015023917A2 (pt) método para determinar a atividade de forma potenciada ativada de substância
MX2015012455A (es) Metodo para el tratamiento de la enfermedad de higado graso.

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal acc. article 33 of ipl - extension of time limit for request of examination expired
B350 Update of information on the portal [chapter 15.35 patent gazette]